Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC ...Middle East

Medscape - News
The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC. Medscape Medical News

Hence then, the article about ivonescimab tops pembro in advanced pd l1 positive nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News